Harrow (HROW) Revenue Growth (3y) (2016 - 2026)
Harrow (HROW) Revenue Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.88 Bn | 87.01 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.92 Bn | 32.18 Bn | 1.97 Bn | 2.84% |
| 3 | Zoetis | 32.31 Bn | 30.37 Bn | 1.62 Bn | 4.19% |
| 4 | Takeda Pharmaceutical | 27.54 Bn | 23.48 Bn | 4.39 Bn | -4.46% |
| 5 | United Therapeutics | 23.07 Bn | 20.91 Bn | 648.10 Mn | 15.52% |
| 6 | RedHill Biopharma | 20.53 Bn | 20.53 Bn | - | - |
| 7 | Viatris | 20.27 Bn | 18.47 Bn | 1.16 Bn | -2.00% |
| 8 | Neurocrine Biosciences | 17.92 Bn | 16.61 Bn | 800.70 Mn | 24.66% |
| 9 | Elanco Animal Health | 12.61 Bn | 12.18 Bn | 785.00 Mn | 2.94% |
| 10 | Harrow | 1.44 Bn | 1.35 Bn | 27.05 Mn | 19.19% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.19% |
| Dec 31, 2025 | 63.65% |
| Sep 30, 2025 | 46.42% |
| Jun 30, 2025 | 39.81% |
| Mar 31, 2025 | 29.31% |
| Dec 31, 2024 | 49.04% |
| Sep 30, 2024 | 38.08% |
| Jun 30, 2024 | 39.23% |
| Mar 31, 2024 | 30.84% |
| Dec 31, 2023 | 35.56% |
| Sep 30, 2023 | 33.51% |
| Jun 30, 2023 | 60.73% |
| Mar 31, 2023 | 30.24% |
| Dec 31, 2022 | 17.27% |
| Sep 30, 2022 | 21.40% |
| Jun 30, 2022 | 19.94% |
| Mar 31, 2022 | 21.64% |
| Dec 31, 2021 | 21.04% |
| Sep 30, 2021 | 20.33% |
| Jun 30, 2021 | 20.42% |